文献速递神经肿瘤

GAL-8、ITGΒ-1与HIF-1α作为胶质瘤无创诊断与预后生物标志物的临床价值

Clinical utility of GAL-8, ITGΒ-1, and HIF-1α as non-invasive diagnostic and prognostic biomarkers for assessing glioma.
PubMed 文献 · J Neurooncol · 2025-06-13

该研究纳入50例高级别胶质瘤、50例低级别胶质瘤和50例健康对照,检测血清GAL-1、GAL-3、GAL-8、ITGβ-1、HIF-1α、MMP-2及MMP-9水平。结果显示胶质瘤组与健康对照组间上述指标均有显著差异,且除HIF-1α外HGG组均显著高于LGG组。作者认为GAL-8、ITGβ-1和HIF-1α可能作为胶质瘤诊断的无创生物标志物组合。

要点

  • 血清GAL-1、GAL-3、GAL-8、ITGβ-1、HIF-1α、MMP-2及MMP-9在胶质瘤与健康对照间存在显著差异。
  • 除HIF-1α外,上述指标在HGG中显著高于LGG,HIF-1α在HGG中有升高趋势但差异不显著。
  • GAL-8、ITGβ-1和HIF-1α可能构成胶质瘤无创诊断的生物标志物 panel。

核心结论

  • GAL-8、ITGβ-1和HIF-1α可能作为胶质瘤诊断的无创生物标志物组合。
  • 血清半乳糖凝集素水平升高可能促进低级别肿瘤向高级别肿瘤进展。

研究设计与样本

  • 研究纳入50例HGG、50例LGG患者和50例健康对照,平均年龄分别为55.48±1.51、41.04±1.66和39.20±1.20岁。
  • 检测新诊断且未治疗的LGG和HGG患者血清GAL-1、GAL-3、GAL-8、ITGβ-1、HIF-1α、MMP-2及MMP-9水平。

主要发现

  • 血清GAL-1、GAL-3、GAL-8、ITGβ-1、HIF-1α、MMP-2及MMP-9水平在胶质瘤组与健康对照组间有显著差异。
  • 血清GAL-1、GAL-3、GAL-8、ITGβ-1、MMP-2及MMP-9水平在HGG中显著高于LGG。
  • 血清HIF-1α水平在肿瘤级别组间无显著差异,但HGG中观察到升高。

临床怎么用

  • GAL-8、ITGβ-1和HIF-1α可作为潜在的无创诊断标志物组合用于胶质瘤评估。
  • 血清半乳糖凝集素水平可能有助于判断低级别胶质瘤向高级别进展的风险。

局限性

  • 原文未报告研究的局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Gliomas have attracted attention as the most common primary tumor of the CNS. Gliomas are made up of glial components of the nervous system. They cause more than 40% of CNS neoplasms, with an increased incidence in the aged 65 years and older. Despite advances in the characterization of the pathogenesis of these tumors, gliomas remain incurable. In recent years, scientific developments have shifted the attention of scientists to the potentials of galectins in glioma biology. Many studies have reported the important functions of galectins in cancer biology, apoptosis, and escape from tumor immunity, metastasis, and angiogenesis. Although few studies in the literature evaluate galectin expressions in gliomas, in-vitro and in-vivo, no study evaluating galectin serum levels in the clinic has been reported. Therefore, within the scope of this project, the roles of GAL-1, GAL-3, and GAL-8 in glioma pathogenesis and the possible link between gliomagenesis and the serum levels of ITGβ-1, HIF-1α, MMP-2, and - 9 parameters associated with hypoxia, angiogenesis, and migration, were evaluated in newly diagnosed and untreated LGG and HGG. METHODS: The study included 50 HGG and 50 LGG patients and 50 healthy controls with mean ages of 55.48 ± 1.51, 41.04 ± 1.66 and 39.20 ± 1.20 years, respectively. RESULTS: Serum GAL-1, -3, -8, ITGβ-1, HIF-1α, MMP-2, and - 9 levels significantly differed between the glioma and healthy control groups. In addition, serum GAL-1, -3, -8, ITGβ-1, MMP-2 and - 9 levels were significantly greater in HGG compared to LGG. Although there was no significant difference in serum HIF-1α levels between the groups with respect to tumor grade, an increase in HGG was observed. This study is the first in the Turkish population in which serum GAL-1, -3, and - 8 levels were clinically evaluated together in glioma pathologies with high angiogenic activity and sheds light on the role of increased serum galectin levels in the promotion of low-grade tumors to high-grade tumors. CONCLUSION: In this respect, we believe that GAL-8, ITGβ-1, and HIF-1α may be usable as a panel of non-invasive biomarkers for glioma diagnosis. Additionally, this study may contribute to studies on glioma treatment and the inhibition of gliomagenesis by bringing a new perspective on the targeting galectins.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Turan T, Emmez ÖH, Kaymaz AM, et al. Clinical utility of GAL-8, ITGΒ-1, and HIF-1α as non-invasive diagnostic and prognostic biomarkers for assessing glioma. J Neurooncol. 2025. PMID: 40512281. doi:10.1007/s11060-025-05110-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。